Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) FCF Margin (2016 - 2025)

Haemonetics has reported FCF Margin over the past 17 years, most recently at 25.73% for Q4 2025.

  • Quarterly results put FCF Margin at 25.73% for Q4 2025, up 1562.0% from a year ago — trailing twelve months through Dec 2025 was 23.37% (up 1617.0% YoY), and the annual figure for FY2025 was 10.47%, down 50.0%.
  • FCF Margin for Q4 2025 was 25.73% at Haemonetics, down from 32.48% in the prior quarter.
  • Over the last five years, FCF Margin for HAE hit a ceiling of 32.48% in Q3 2025 and a floor of 9.84% in Q2 2024.
  • Median FCF Margin over the past 5 years was 10.75% (2024), compared with a mean of 10.01%.
  • Biggest five-year swings in FCF Margin: plummeted -3755bps in 2021 and later skyrocketed 2114bps in 2024.
  • Haemonetics' FCF Margin stood at 9.44% in 2021, then skyrocketed by 65bps to 15.58% in 2022, then tumbled by -129bps to 4.52% in 2023, then surged by 324bps to 10.1% in 2024, then soared by 155bps to 25.73% in 2025.
  • The last three reported values for FCF Margin were 25.73% (Q4 2025), 32.48% (Q3 2025), and 4.24% (Q2 2025) per Business Quant data.